TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8517380

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 24187

Group type: COMPARATOR
Intervention: Control (no thrombolytic agents)
Number of subjects: 24187
Study: 3327930

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.06 mg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg i.v.)
Number of subjects: 8
Study: 28764618

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study: 27079993

Group type: EXPERIMENTAL
Intervention: Psychiatrists' ability to provide mental health services
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Psychiatrists' ability to provide inpatient and other treatments
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Time during patient visits
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Sufficient visits to meet clinical needs
Number of subjects: 1099
Study: 25467772

Group type: EXPERIMENTAL
Intervention: Community paramedic intervention (regular home visits, health assessments, evidence-based treatments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community paramedic intervention
Number of subjects: 0
Study: 22183059

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA, 10 U
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA, 30 U
Number of subjects: 90
Study: 21110850

Group type: EXPERIMENTAL
Intervention: rhAPC (24 μg/kg/hour) administered intravenously from 1 hour post injury until the end of the 24‐hour experiment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhAPC (24 μg/kg/hour)
Number of subjects: 21
Study: 18368409

Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises for 15 patients for 8 weeks in clinic
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group of 25 patients with BJHS
Number of subjects: 40
Study: 15599642

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) - hylan G-F 20, Synvisc, 3 weekly injections into one or both knees (30 knees)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline, 3 intra-articular injections of 2 ml saline at the same intervals (10 knees)
Number of subjects: 30
Study: 12712028

Group type: EXPERIMENTAL
Intervention: On-deflate method
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Off-deflate method
Number of subjects: 75
Study: 10985480

Group type: EXPERIMENTAL
Intervention: IFNalpha 2b (5 MU sqm/daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IFNalpha 2b plus low-dose AraC
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IFNalpha/AraC therapy
Number of subjects: 43
Study: 8803740

Group type: EXPERIMENTAL
Intervention: Educational videotape about PSA testing and treatment uncertainties (N = 184 in study 1, N = 103 in study 2)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Educational videotape (N = 103 in study 2)
Number of subjects: 367

Group type: COMPARATOR
Intervention: No videotape (N = 93 in study 2)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Another videotape (N = 185 in study 1)
Number of subjects: 367
Study: 1864332

Group type: EXPERIMENTAL
Intervention: Vibration of the right triceps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibration of the right biceps
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 0
Study: 6424229

Group type: EXPERIMENTAL
Intervention: Cimetidine (05 mg/kg/h) after an initial bolus of 1.5 mg/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Pentagastrin (0.02, 0.2, and 2.0 micrograms/kg/h) alone
Number of subjects: 5
Study: 30928275

Group type: EXPERIMENTAL
Intervention: Continuous FNB 48 h + PCA
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Single‐shot FNB + PCA
Number of subjects: 135

Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 135
Study: 28865249

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose HT (0.5 mg 17β‐estradiol/2.5 mg dydrogesterone)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard HT (1 mg 17β‐estradiol/5 mg dydrogesterone)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 25617253

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6 mg per day for days 1-7, flexibly dosed 3, 6, or 9 mg per day from week 2 to end of study)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Aripiprazole (2 mg per day for days 1-2, 5 mg per day for days 3-4, 10 mg per day for days 5-7, flexibly dosed 5, 10, or 15 mg per day from week 2 to end of study)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 228

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 228
Study: 23528553

Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 21641274

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Laboratory-guided preemptive therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Prophylaxis
Number of subjects: 64
Study: 19334654

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with nerve stimulation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional multiple nerve stimulation
Number of subjects: 129
Study: 17425158

Group type: EXPERIMENTAL
Intervention: Weight-adjusted unfractionated heparin (Heparin-'Biochemie' 25.000 IU/5 ml)
Number of subjects: 30
Study: 11807634

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g plus gentamicin 5 mg/kg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Cefepime 2 g t.i.d. plus gentamicin 5 mg/kg q.d.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus gentamicin
Number of subjects: 211

Group type: COMPARATOR
Intervention: Cefepime plus gentamicin
Number of subjects: 211
Study: 10414691

Group type: EXPERIMENTAL
Intervention: Compression dressing
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Compression dressing (MRM patients)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard dressing (MRM patients; control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Compression dressing (BCT patients)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard dressing (BCT patients; control)
Number of subjects: 135
Study: 7589023

Group type: EXPERIMENTAL
Intervention: Molsidomine 4 mg (2 tablets, given 6 h apart)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Molsidomine 16 mg (sustained-release, once daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1689135

Group type: EXPERIMENTAL
Intervention: 5% permethrin cream
Number of subjects: 467

Group type: COMPARATOR
Intervention: 1% lindane lotion
Number of subjects: 467
Study: 225750

Group type: EXPERIMENTAL
Intervention: MSH/ACTH 4-10 (30 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diluent control solution
Number of subjects: 24
Study: 6578828

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 32
Study: 31037716

Group type: EXPERIMENTAL
Intervention: Specific interventions at resection with primary anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29723767

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg oral/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 44
Study: 27371945

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 3978

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 3978
Study: 24480113

Group type: EXPERIMENTAL
Intervention: Contraceptive containing 20mcg of ethinyl estradiol and 3mg of drospirenone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non‐hormonal contraceptive methods
Number of subjects: 69
Study: 22763473

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg per day titrated to 20 mg per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amlodipine (5 mg per day titrated to 10 mg per day)
Number of subjects: 35
Study: 20571820

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg twice per week for 8 weeks
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.25 mg twice per week for 8 weeks
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.125 mg twice per week for 8 weeks
Number of subjects: 164

Group type: COMPARATOR
Intervention: No maintenance treatment (Group I)
Number of subjects: 164
Study: 17962596

Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin for 2 weeks followed by 40 mg for 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16169304

Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid (1 g bid)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Amoxycillin (1 g bid) alone
Number of subjects: 172
Study: 14501103

Group type: EXPERIMENTAL
Intervention: High-speed artificial gravity (short-radius centrifugation)
Number of subjects: 0
Study: 10326778

Group type: EXPERIMENTAL
Intervention: Nicotine patch (Nicotrol) 5 mg/day during week 1, 10 mg/day during weeks 2 and 3, 5 mg/day during week 4
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 7575754

Group type: EXPERIMENTAL
Intervention: Enteric-coated microcapsules (A)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rapid-release film-coated tablet (B)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sustained-release tablet (C)
Number of subjects: 9
Study: 1934003

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day
Number of subjects: 100
Study: 6972824

Group type: EXPERIMENTAL
Intervention: Phenoprocoumon (oral anticoagulation) starting on the seventh postoperative day
Number of subjects: 173

Group type: COMPARATOR
Intervention: No anticoagulation (control group)
Number of subjects: 173
Study: 31542988

Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement (CAE) intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: BD-specific educational program (EDU)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Change over time in TRQ between older and younger participants by treatment arm (CAE and EDU)
Number of subjects: 184
Study: 30284015

Group type: EXPERIMENTAL
Intervention: Beacon model of integrated care delivered by GPs with special interests
Number of subjects: 305

Group type: COMPARATOR
Intervention: Usual care delivered by a hospital outpatient department
Number of subjects: 305
Study: 29767694

Group type: EXPERIMENTAL
Intervention: Serum α-carotene levels (per log unit (μg/dL) increase)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Serum α-carotene concentrations at or above the US average (2.92 μg/dL)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: γ-tocopherol concentrations at or above the US average
Number of subjects: 1228
Study: 26863227

Group type: EXPERIMENTAL
Intervention: Depletion condition (video-viewing attention control task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 24785401

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study: 22207690

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of low trough imatinib levels (< 1200 ng/mL) and low OCT-1 activity
Number of subjects: 100
Study: 19560866

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) for 3 days (N=15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 8 hours of sleep per night (N=9)
Number of subjects: 24
Study: 18204133

Group type: EXPERIMENTAL
Intervention: 200 microg HFA‐BDP once daily (o.d.)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 100 microg HFA‐BDP twice daily (b.i.d.)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 16179873

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m) plus treosulfan (2500 or 3000 mg/m2) in cohort 1
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m) plus treosulfan (3500 or 4000 mg/m2) in cohort 2
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cohort 1 (treosulfan dose <=3000 mg/m2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cohort 2 (treosulfan dose >=3500 mg/m2)
Number of subjects: 33
Study: 12114041

Group type: EXPERIMENTAL
Intervention: Fel d 1 peptides (90 microg in increasing divided doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10220224

Group type: EXPERIMENTAL
Intervention: Immunocytochemistry with antibodies recognizing NR1 or NR2A/B subunits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electron-microscopic observations
Number of subjects: 0
Study: 7787130

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate, single IV doses ranging from 0.30 to 0.60 mg kg‐1 on day 1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate, multiple IV doses ranging from 0.60 to 1.20 mg kg‐1 d‐1 on days 2-9
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2191584

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg twice daily for 4 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 381954

Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCRN) 250 mg once or twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 50 mg once or twice daily
Number of subjects: 14
Study: 31994703

Group type: EXPERIMENTAL
Intervention: Selatogrel 8 mg
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Selatogrel 16 mg
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Selatogrel
Number of subjects: 345
Study: 31627901

Group type: EXPERIMENTAL
Intervention: General anesthesia plus bilateral superficial cervical plexus block (GS; n=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: General anesthesia (GA; n=23)
Number of subjects: 46
Study: 28686000

Group type: EXPERIMENTAL
Intervention: Near-infrared ray abdominal belt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hot packs
Number of subjects: 0
Study: 25902768

Group type: EXPERIMENTAL
Intervention: Forced exercise cycling (30% faster than voluntary rate, 3 times per week for 8 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Voluntary exercise cycling (3 times per week for 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 100
Study: 23811305

Group type: EXPERIMENTAL
Intervention: HIGH-dose steroid (prednisolone 5mg/kg/day, n=44)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Steroids (LOW-dose and HIGH-dose)
Number of subjects: 153

Group type: COMPARATOR
Intervention: NO steroid (n=91)
Number of subjects: 153
Study: 21269291

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1723
Study: 17905421

Group type: EXPERIMENTAL
Intervention: Bortezomib 0.8 mg/m2 with carboplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m2 with carboplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 with carboplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m2 with carboplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall treatment with bortezomib and carboplatin
Number of subjects: 21
Study: 16925896

Group type: EXPERIMENTAL
Intervention: HPV16/18 VLP vaccine
Number of subjects: 2404

Group type: COMPARATOR
Intervention: Hepatitis A control vaccine
Number of subjects: 2404

Group type: COMPARATOR
Intervention: Unvaccinated control
Number of subjects: 2404
Study: 12933352

Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OFF
Number of subjects: 18
Study: 11885176

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinses
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 663

Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 663
Study: 8991863

Group type: EXPERIMENTAL
Intervention: Duplicated (J) reservoir
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quadruplicated (W) reservoir
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smaller (30 cm) reservoirs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Larger (40 cm) reservoirs
Number of subjects: 60
Study: 1307585

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily
Number of subjects: 60
Study: 3976820

Group type: EXPERIMENTAL
Intervention: Activity therapy (n = 7)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Verbal therapy (n = 6)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal milieu therapy (control group, n = 6)
Number of subjects: 19
Study: 30978259

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) targeting inhibitory control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anodal dlPFC-tDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tDCS on inhibitory control accuracy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tDCS on working memory (WM) speed
Number of subjects: 10
Study: 29781385

Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 1656
Study: 26103919

Group type: EXPERIMENTAL
Intervention: Regular home visits (treatment group)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Standard community services (control group)
Number of subjects: 755
Study: 24494790

Group type: EXPERIMENTAL
Intervention: Hypoxic training for 2 weeks (6 days week(-1))
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hypoxic training for 4 weeks (3 days week(-1))
Number of subjects: 21
Study: 23810357

Group type: EXPERIMENTAL
Intervention: Add-on quetiapine XR (300 mg/day)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Quetiapine XR monotherapy (300 mg/day)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Add-on lithium (0.6-1.2 mmol/L)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Add-on quetiapine XR
Number of subjects: 688
Study: 21988865

Group type: EXPERIMENTAL
Intervention: Intervention group (SOC model consultations)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 61
Study: 19019888

Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy (8 mg/kg every 4 weeks)
Number of subjects: 143
Study: 17073813

Group type: EXPERIMENTAL
Intervention: G-CSF therapy
Number of subjects: 0
Study: 14696004

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography (MRCP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 10
Study: 10686224

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg every 3 h for a maximum of five doses in 24 h
Number of subjects: 148

Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 6 h for a maximum of three doses in 24 h
Number of subjects: 148
Study: 9349857

Group type: EXPERIMENTAL
Intervention: 16 mg betahistine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 32 mg betahistine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 64 mg betahistine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7997605

Group type: EXPERIMENTAL
Intervention: Color-Doppler US
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Local treatment
Number of subjects: 29
Study: 2899660

Group type: EXPERIMENTAL
Intervention: azathioprine 2.5 mg/kg daily
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 31980883

Group type: COMPARATOR
Intervention: Voice therapy and medicament therapy (group 1)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Voice therapy, medicament therapy, and transcutaneous electrical stimulation (group 2)
Number of subjects: 149
Study: 30133685

Group type: EXPERIMENTAL
Intervention: Aquanet EC‐2000®
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mannitol solution
Number of subjects: 200
Study: 27305912

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg PO daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Untreated historical controls
Number of subjects: 35
Study: 26549714

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 120 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (all doses)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 24419872

Group type: EXPERIMENTAL
Intervention: Inner speech
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heard speech
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Different verse types (hexameter and alliteration)
Number of subjects: 29
Study: 22409340

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 11
Study: 20136764

Group type: EXPERIMENTAL
Intervention: Football training (F)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Running training (R)
Number of subjects: 47
Study: 18361658

Group type: EXPERIMENTAL
Intervention: Collaborative recall with spouses
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nominal groups (spouses remembering alone)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Collaborative recall
Number of subjects: 2
Study: 16204903

Group type: COMPARATOR
Intervention: 5% lignocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% minoxidil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of 5% lignocaine and 0.5% minoxidil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 90